WW International (WW) Declined in Q3. Here’s Why

Group 1: Portfolio Performance - Kingdom Capital Advisors reported a portfolio recovery in Q3 2025, achieving a return of 20.78% (net of fees), outperforming the Russell 2000 TR (12.39%), S&P 500 TR (8.12%), and NASDAQ 100 TR (9.01%) [1] - Since inception, the portfolio has compounded at 21.06% (net of fees), significantly higher than the Russell 2000 TR (4.60%), S&P 500 TR (11.46%), and NASDAQ 100 TR (13.48%) [1] Group 2: WW International, Inc. (NASDAQ:WW) Overview - WW International, Inc. (NASDAQ:WW) experienced a one-month return of -11.21% and a three-month decline of 22.97%, with a closing stock price of $26.15 and a market capitalization of $261.158 million as of October 13, 2025 [2] - The company is identified as the biggest detractor in Q3 2025, following its bankruptcy earlier in the year, but it is viewed as a historically attractive opportunity [3] Group 3: Market Position and Future Outlook - Despite concerns regarding the sustainability of growth post-bankruptcy and recent FDA restrictions on GLP-1 compounding, there is intrigue around WW International's clinical business growth [3] - Partnerships with Eli Lilly and Novo Nordisk provide some confidence in the company's ability to navigate the evolving GLP-1 market, supported by a repaired balance sheet [3] - The company is not listed among the 30 Most Popular Stocks Among Hedge Funds, with a belief that certain AI stocks present greater upside potential and lower downside risk [4]